Insider · CIK 0001366268
Jon Faiz Kayyem
director
Files at BDSX (BIODESIX INC), INBX (Inhibrx Biosciences, Inc.). First filing Nov 22, 2024, latest Sep 23, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
4 / 0
$3.1M bought, $0 sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
INBX: Inhibrx Biosciences, Inc.
INBXOct 9, 2026 · close 95.01
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 46Moderate | Inhibrx Biosciences, Inc. | $500k 5,000 shares | +1% | - | |
| 53Moderate | Inhibrx Biosciences, Inc. | $500k 5,000 shares | +1% | - | |
| 49Moderate | Inhibrx Biosciences, Inc. | $568k 5,000 shares | +1% | - | |
| 50Moderate | INBXbuy Inhibrx Biosciences, Inc. | $1.5M 107,186 shares | +660% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 23, 2026 | INBX Inhibrx Biosciences, Inc. | POpen-market purchase Common Stockindirect: By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust | +5,000 | $100.00 | $500k | 434,360 | 19 d ago |
| Jun 3, 2026 | INBX Inhibrx Biosciences, Inc. | AGrant or award Stock Option (right to buy)derivative | +10,000 | $0.00 | $0 | 10,000 | 24 d ago |
| Sep 16, 2026 | INBX Inhibrx Biosciences, Inc. | POpen-market purchase Common Stockindirect: By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust | +5,000 | $100.00 | $500k | 429,360 | 25 d ago |
| Sep 8, 2026 | INBX Inhibrx Biosciences, Inc. | POpen-market purchase Common Stockindirect: By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust | +5,000 | $113.52 | $568k | 424,360 | 34 d ago |
| Jan 2, 2026 | BDSX BIODESIX INC | AGrant or award Restricted Stock Unitsderivative | +5,443 | $0.00 | $0 | 5,443 | Jan 6, 2026 |
| Jan 2, 2026 | BDSX BIODESIX INC | AGrant or award Stock Options (Right to Buy)derivative | +6,354 | $0.00 | $0 | 6,354 | Jan 6, 2026 |
| May 28, 2025 | INBX Inhibrx Biosciences, Inc. | AGrant or award Stock Option (right to buy)derivative | +15,000 | $0.00 | $0 | 15,000 | May 29, 2025 |
| May 20, 2025 | BDSX BIODESIX INC | AGrant or award Restricted Stock Unitsderivative | +68,621 | $0.00 | $0 | 68,621 | May 22, 2025 |
| May 20, 2025 | BDSX BIODESIX INC | AGrant or award Stock Options (Right to Buy)derivative | +42,010 | $0.00 | $0 | 42,010 | May 22, 2025 |
| Mar 27, 2025 | INBX Inhibrx Biosciences, Inc. | GGift Common Stockindirect: By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust | -90,000 | $0.00 | $0 | 419,360 | Mar 28, 2025 |
| Dec 16, 2024 | INBX Inhibrx Biosciences, Inc. | GGift Common Stockindirect: By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust | -500,000 | $0.00 | $0 | 509,360 | Dec 17, 2024 |
| Dec 16, 2024 | INBX Inhibrx Biosciences, Inc. | GGift Common Stockindirect: By Jon Faiz Kayyem Revocable Trust | +250,000 | $0.00 | $0 | 250,000 | Dec 17, 2024 |
| Dec 16, 2024 | INBX Inhibrx Biosciences, Inc. | GGift Common Stockindirect: By Paige Gates-Kayyem Revocable Trust | +250,000 | $0.00 | $0 | 250,000 | Dec 17, 2024 |
| Dec 6, 2024 | INBX Inhibrx Biosciences, Inc. | GGift Common Stockindirect: By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust | -52,000 | $0.00 | $0 | 1,009,360 | Dec 6, 2024 |
| Nov 19, 2024 | INBX Inhibrx Biosciences, Inc. | POpen-market purchase Common Stockindirect: By Child A | +34,843 | $14.23 | $496k | 51,093 | Nov 22, 2024 |
| Nov 19, 2024 | INBX Inhibrx Biosciences, Inc. | POpen-market purchase Common Stockindirect: By Child B | +34,843 | $14.23 | $496k | 51,093 | Nov 22, 2024 |
| Nov 20, 2024 | INBX Inhibrx Biosciences, Inc. | POpen-market purchase Common Stockindirect: By Child A | +18,750 | $14.19 | $266k | 69,843 | Nov 22, 2024 |
| Nov 20, 2024 | INBX Inhibrx Biosciences, Inc. | POpen-market purchase Common Stockindirect: By Child B | +18,750 | $14.19 | $266k | 69,843 | Nov 22, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.